Abstract
In recent years, many significant advances have been made on molecular target therapy to aim directly at epidermal growth factor receptors and vascular endothelial growth factor in breast cancers. Clinical studies of such agents as trastuzumab, lapatinib, erlotinib and bevacituzumab have been widely conducted. This paper will review the recent research progress related to targeted therapy.
Similar content being viewed by others
References
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. N Engl J Med 2005; 353: 1673–1684.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer. N Engl J Med 2005; 353: 1659–1672.
Austin CD, DeMaziere AM, Pisacane PI, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004; 15: 5268–5282.
Wen XF, Yang G, Mao W, et al. HER-2 signaling modulates the equilibrium between pro-and antiangiogenic factors via distinct pathways: implications for HER-2-targeted antibody therapy. Oncogene 2006; 25: 6986–6996.
Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment ofHER-2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006; 94: 259–267.
Gabos Z, Sinha R, Hanson J, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006; 24: 5658–5663.
Furukawa K, Ito Y, Takahashi S, et al. Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience. Breast Cancer 2006; 13: 329–333.
Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64: 2343–2346.
Walshe JM, Denduluri N, Berman AW, et al. A phase II trial with trastuzumab and pertuzumab in patients with HER-2-overexpressed locally advanced and metastatic breast cancer. Clin Breast Cancer 2006; 6: 535–539.
Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145–147.
Borgstrom P, Gold DP, Hillan KJ, et al. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999; 19: 4203–4214.
Atiqur Rahman M, Toi M. Anti-angiogenic therapy in breast cancer. Biomed Pharmacother 2003; 57: 463–470.
Uzzan B, Nicolas P, Cucherat M, et al. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004; 64: 2941–2955.
Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30: 117–124.
Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792–799.
Miller KD: E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 2003; 3: 421–422.
Perez EA, Hillman DW, Kugler JW, et al. North Central cancer treatment group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first line chemotherapy for patients with metastatic breast cancer. Breast Cancer Research and Treatment 2006; Supplement 1, Abstract #2069.
Overmoyer B, Silverman P, Leeming R, et al. Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. Breast Cancer Res Treatment 2004; 88: S106, Abstract #2088.
Wedam SB, Low JA, Yang SX, et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. J Clin Oncol 2006; 24: 769–777.
Konecny GE, Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004; 10: 1706–1716.
Pegram M, Yeon C, Ku N, et al. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER-2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res Treatment 2004; 88: S124, Abstract #3039.
Pegram M, Chan D, Dichmann RA, et al. Phase II combined biological therapy targeting the HER-2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER-2-amplified breast cancer. Breast Cancer Research and Treatment 2006; Supplement 1: Abstract #3019.
Nakamura H, Takamori S, Fujii T, et al. Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer. Cancer Lett 2005; 230: 33–46.
Ciardiello F, Troiani T, Caputo F, et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 2006; 94: 1604–1609.
Karen E and Lackey KE. Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Current Topics in Medicinal Chemistry 2006; 6: 435–460.
Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth receptor bound to GW572016 (lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64: 6652–6659.
Burris HA 3rd, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23: 5305–5313.
Blackwell KL, Kaplan EH, Franco SX, et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 2004; 22: 14S.
Gomez HL, Chavez MA, Doval DC, et al. Results from a phase II randomized study of lapatinib as firstline treatment for patients with ErbB2-amplified advanced or metastatic breast cancer. Breast Cancer Res and Treat 2006; 100: S68.
Spector NL, Blackwell K, Hurley J, et al. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response. Proc Am Soc Clin Oncol 2006; 24: 18S.
Perez EA, Byrne JA, Hammond IW, et al. Results of an analysis of cardiac function in 2,812 patients treated with lapatinib. Proc Am Soc Clin Oncol 2006; 24: 18S.
Siegel-Lakhai WS, Beijnen JH, Vervenne WL, et al. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clin Cancer Res 2007; 13: 4495–4502.
Iwata H, Toi M, Fujiwara Y, et al. Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer. Breast Cancer Res and Treat 2006; 100: S68.
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER-2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733–2743.
Cristofanilli M, Boussen H, Baselga J, et al. A phase II combination study of lapatinib and paclitaxel as a neo adjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Breast Cancer Res and Treat 2006; 100: S5.
Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumabtreated breast cancer cells. Cancer Res 2006; 66: 1630–1639.
Xia W, Gerard CM, Liu L, et al. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005; 24: 6213–6221.
Storniolo A, Burris H, Pegram M, et al. A phase I, open-label study of lapatinib (GW 572016) plus trastuzumab; a clinically active regimen. Proc Am Soc Clin Oncol 2005; 23: 16S.
Cabebe E and Wakelee H. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis. Drugs Today (Barc) 2006; 42: 387–398.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yang, S., Zhao, B. Research progress in the use of drugs for breast cancer targeted therapy. Chin. J. Clin. Oncol. 5, 320–325 (2008). https://doi.org/10.1007/s11805-008-0320-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11805-008-0320-z